$LFMDP

LifeMD (LFMD) will release Q3 2026 financial results on November 9, 2026, before market open, followed by a conference call at 8:30 a.m. ET. The company provides virtual primary care and pharmacy services.

LifeMD (LFMD) partnered with AT&T to offer free virtual-health memberships to 29 million eligible customers in 11 states, with a nationwide expansion planned for 2027. The $19 monthly fee is waived, but services like visits and prescriptions remain payable. LifeMD aims to convert access into recurring demand for paid care, potentially reducing acquisition costs and benefiting from repeat consultations. The phased rollout allows for measuring enrollment and utilization before expansion.

LifeMD (LFMD) reported Q2 2026 revenue of $47.3M, within guidance ($47M-$50M) but down 4% YoY, and an adjusted EBITDA loss of about $3.5M. Full-year revenue guidance was cut to $205.5M-$212.5M and adjusted EBITDA to negative $6M to breakeven. Active subscribers were 356,000. Cash was $25.1M.

LifeMD (Nasdaq: LFMD) reported Q2 2026 revenue of $47.3M, below the $49.16M consensus estimate, with GAAP EPS loss of $0.16 versus a $0.01 EPS expectation. The company posted an adjusted EBITDA loss and cut full-year 2026 guidance to $205.5M–$212.5M revenue and negative $6M to breakeven adjusted EBITDA. LFMD shares fell after the release.

LifeMD, Inc. (LFMD) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 LifeMD Reports Second Quarter 2026 Results ● Second quarter 2026 revenue of $47.3 million, within the Company’s guidance range of $47 million to $50 million; adjusted EBITDA loss of approximately $3.5 million, improving approximately 21% sequentially. ● Approximately

B. Riley Securities reiterated LifeMD Inc. as its top digital health pick after its 26th Annual Institutional Investor Conference. The firm rates LFMD Buy, with a $10 price target, citing a telehealth collaboration with Antares for XYOSTED, Medicare GLP-1 coverage via Humana, and potential FDA compounding changes. It also cites LifeMD Q1 2026 revenue of $50.2M and EPS of -$0.20.

LifeMD, Inc. (Nasdaq: LFMD) said its board authorized a cash dividend on its 8.875% Series A Cumulative Perpetual Preferred Stock (LFMDP) of $0.5546875 per share. The dividend will be paid July 15, 2026, to holders of record as of July 3, 2026.

LifeMD (Nasdaq: LFMD) appointed Umesh Sripad as Chief Technology Officer effective immediately, according to the company. He will lead technology strategy, platform transformation, AI enablement, cybersecurity, data infrastructure, and scalability. LifeMD said it has grown to a 50-state virtual primary/specialty care and pharmacy platform serving nearly 350,000 patients. The company will grant 150,000 RSUs as an inducement.

LifeMD, Inc. (LFMD) has awarded its Chief Financial Officer, Atul Kavthekar, 337,500 restricted stock units (RSUs) as part of a compensation grant. These RSUs were granted at a price of $0.00 per share and will vest in three equal tranches on March 16, 2027, March 16, 2028, and March 16, 2029, aligning his compensation with multi-year service. Following this grant, Kavthekar directly holds 337,500 shares.

LifeMD Inc. (LFMD) reported a strong Q4 and full-year 2025, with a 25% annual revenue increase and strategic advancements in AI and healthcare services. Despite a GAAP net loss for the quarter and anticipated Q1 2026 EBITDA loss due to high marketing investments in its GLP-1 weight loss business, the company is optimistic about future growth driven by new patient acquisitions, expanding services like Oral Wegovy, and AI integration. LifeMD is entering 2026 with a strong balance sheet, nearly 323,000 active subscribers, and no debt.